The IRF2BPL Knockout SK-HEP-1 Polyclonal Cells represent a genetically modified human liver adenocarcinoma-derived cell population in which the IRF2BPL gene has been disrupted via CRISPR/Cas9-mediated genome editing. This polyclonal knockout pool, generated by introducing Cas9 nuclease and guide RNAs targeting critical regions of IRF2BPL, provides a heterogeneous population harboring diverse loss-of-function alleles. As a bulk-edited product, it enables functional assessment of IRF2BPL deficiency without clonal artifacts, preserving population-level variability that more closely mimics complex tumor microenvironments. The knockout model is suitable for interrogating IRF2BPL-dependent regulatory networks in hepatocellular carcinoma research and neurodevelopmental disorder modeling.
SK-HEP-1 cells are a widely characterized human liver adenocarcinoma cell line originally isolated from the ascitic fluid of a patient with hepatocellular carcinoma. This epithelial tumor line displays robust adherent growth and is extensively employed in in vitro studies of hepatic carcinogenesis, drug metabolism, and cancer signaling. The SK-HEP-1 background is particularly valuable for exploring the contributions of transcriptional corepressors to malignant phenotypes, given its well-documented activation of pathways such as STAT3 and MAPK. Use of this host cell line in the knockout context allows direct investigation of how IRF2BPL loss influences tumor cell proliferation, apoptosis resistance, and invasive behavior.
IRF2BPL (interferon regulatory factor 2 binding protein-like) encodes a transcriptional corepressor that forms complexes with IRF2 and histone deacetylases such as HDAC1 to modulate chromatin structure at target promoters. Through this interaction, it represses transcription of interferon-responsive genes following interferon gamma (IFNG) stimulation via the JAK-STAT pathway. Additionally, IRF2BPL functions downstream of Notch signaling by fine-tuning the expression of HES1 and other Notch targets, potentially through direct interaction with RBPJ?Ccofactor assemblies. The protein contains a RING finger domain that confers E3 ubiquitin ligase activity, enabling it to ubiquitinate and regulate the stability of key cell cycle regulators like CDKN1A. Upstream activation by STAT1-mediated signaling and interplay with interferon regulatory networks position IRF2BPL at a critical node linking innate immunity, development, and oncogenic control.
In the SK-HEP-1 hepatocellular carcinoma background, disruption of IRF2BPL is predicted to relieve transcriptional repression of interferon-stimulated genes and alter Notch pathway output, thereby impacting cell cycle progression and tumorigenic potential. Given the gene’s involvement in neurodevelopmental disorder with regression, abnormal movements, and epilepsy (NEDAMM), this polyclonal knockout model offers a unique platform to dissect tissue-specific roles of IRF2BPL. In liver cancer cells, loss of its corepressor function may enhance proliferative signaling and modulate sensitivity to interferon-based therapies. The polyclonal nature of the edited population enables detection of heterogeneous responses and identification of downstream effectors that drive liver adenocarcinoma progression, while also providing a cost-effective tool for pooled functional screening.
Researchers can employ the IRF2BPL Knockout SK-HEP-1 Polyclonal Cells in a wide range of assays to mechanistically define IRF2BPL-dependent pathways. Western blotting and RT-qPCR are ideal for confirming target gene disruption at the protein and transcript levels, while RNA-seq enables global transcriptomic profiling to uncover altered interferon and Notch gene signatures. Functional studies can utilize Annexin V flow cytometry to measure apoptotic responses, MTS/MTT proliferation assays to monitor growth changes, and luciferase reporter assays for IRF2 transcriptional activity. Co-immunoprecipitation with IRF2 and HDAC1 facilitates mapping protein?Cprotein interactions within the corepressor complex. Migration and invasion assays further extend the model’s utility for metastatic behavior analysis. For additional details or to request a quote, please contact Ascent Research.
